1. On 11/06/2026, Commerce published in the Federal Register (91 FR 70053) its preliminary determination of sales at less than fair value and preliminary affirmative determination of critical circumstances in the antidumping duty investigation of N-Cyclohexylbenzothiazole-2-Sulfenamide from the People's Republic of China (China). 2. The products covered by this investigation are described in message 6159405, dated 06/08/2026. 3. This proceeding has been assigned case number A-570-234. 4. Commerce has preliminarily determined that critical circumstances exist for imports of subject merchandise from the exporter identified below. Accordingly, for imports of such merchandise, CBP shall suspend liquidation of such shipments entered, or withdrawn from warehouse, for consumption on or after 08/08/2026 (90 days prior to the date of FR publication of the preliminary determination) and shall require, for such entries, a cash deposit equal to the percentage of entered value for the exporter listed below. Exporter: China-Wide Entity Case number: A-570-234-000 Cash deposit rate: 281.69% 5. For all other entries of N-Cyclohexylbenzothiazole-2-Sulfenamide from China, the following cash deposit instructions apply: A. For all Chinese exporters of N-Cyclohexylbenzothiazole-2-Sulfenamide from China which have not received their own rate, the cash deposit rate will be the Country-wide China rate. B. For all non-Chinese exporters of N-Cyclohexylbenzothiazole-2-Sulfenamide from China which have not received their own rate, the cash deposit rate will be the rate applicable to the exporter/producer combinations that supplied that non-Chinese exporter. 6. If there are any questions by the importing public regarding this message, please contact the Call Center for the Office of AD/CVD Operations, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce at (202) 482-0984. CBP ports should submit their inquiries through authorized CBP channels only. (This message was generated by OIX:EL.) 7. There are no restrictions on the release of this information. Alexander Amdur